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Abstract
Background: Behçet’s disease (BD) is an inflammatory multisystem disease with 
unknown etiology, and consists of a TRIAD comprising recurrent oral ulcers, genital 
ulcers, and uveitis. In some cases, the disease affects the central nervous system, 
called Neuro‑Behçet Disease (NBD). Few cases of NBD simulating a brain tumor 
have been previously reported.
Case Description: Here, we describe the case of a 46‑year‑old male patient with 
a previous diagnosis of brain tumor who was later diagnosed for BD.
Conclusion: This case highlights the importance of differential diagnosis of lesions 
with tumoral features. Checking for the possibility of NBD may help avoiding biopsy 
in these types of cases.
Key Words: Behçet syndrome, brain tumor‑like lesions, brain disease diagnosis, 
neuro‑Behçet Disease
INTRODUCTION
Behçet’s disease (BD) is an inflammatory multisystem disease 
of unknown etiology with periods of relapses and remissions. 
The disease was named in the memory of “Hulusi Behçet,” 
a Turkish dermatologist who has described a trisymptom 
complex, characterized by recurrent oral ulcers, genital ulcers, 
and uveitis.[8] Later, studies demonstrated the multisystemic 
pattern of this condition, which can compromise vessels, 
joints, the gastrointestinal tract, the heart, lungs, and central 
nervous system (CNS). The disease can affect all sizes of 
blood vessels, on both arterial and venous sides.
Few cases of NBD mimicking a brain tumor have been 
reported. We report a case of a patient with a previous 
diagnostic of brain tumor who was diagnosed as BD. We 
discuss the case and review the literature regarding this 
rare presentation of BD.
CASE REPORT
MR, male, 46‑year‑old, came to the hospital with a 
complaint of subacute hemiparesis in the left lower limb, 
accompanied by mental confusion.
In the past, he had the same clinical presentation associated 
to oral ulcers. He was submitted to brain MRI and to lumbar 
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puncture. The brain MRI showed a T2‑hyperintense lesion 
in the regions of mesencephalon and right parahippocampus 
[Figure 1]. The cerebrospinal fluid (CSF) showed sterile 
monocytic pleocytosis. In the past, it was suspected of 
herpetic encephalitis, and he completed a treatment with 
intravenous Acyclovir, with improvement of the symptoms. 
One year later, the patient had a similar clinical and 
radiologic condition, being treated again with acyclovir 
and showing resolution of symptoms. Seven months later, 
there was a new relapse, and prophylactic Valacyclovir was 
started. When the patient entered the hospital, he showed 
paralytic mydriasis in the right eye, left supranuclear facial 
paresis, and paresis in the left lower limb with hyperreflexia. 
Ophthalmologic evaluation was unremarkable. In the 
previous medical history, there was a clear story of recurrent 
painful oral ulcers (6 episodes/month – in the worst moment 
of the disease) that healed in seven days and acneiform 
lesions in dorsum. No genital ulcers or visual alterations were 
reported. At this time in the hospital, the patient has no oral 
ulcers. Cell blood count, rheumatologic tests, syphilis, HIV, 
hepatitis serology, and Mantoux’s reaction were performed. 
All were negative. A pathergy test was also performed, 
with negative results. CSF showed 28 leukocytes (66% 
neutrophils and 44% monocytes) and 46 mg/dL of proteins. 
Cultural tests and PCRs for infectious agents were negative. 
Brain MRI showed an hyperintense T2 lesion at midbrain 
peduncle, simulating a mesencephalic tumor [Figure 2]. 
A neurosurgical consultation was performed. A brain biopsy 
was discussed, but the team decided to submit the patient 
to a conservative treatment, administering corticosteroids for 
a possible BD. He was submitted to IV methylprednisolone 
in a dose of 1 g daily during 5 days. His symptoms remitted 
completely after 10 days.
DISCUSSION
Epidemiology
Generally, BD starts in the third or fourth decade of 
life,[2] with similar rates for males and females. There is 
a higher prevalence in countries along the “Silk Route”, 
extending from Asia (Japan, China, Russia) to the Middle 
Eastern and Mediterranean countries.[4] Turkey has the 
highest prevalence (42/10,000) in population with 12 years 
or older et al.[7] In the western countries, the prevalence 
is much lower.[29] Environmental and genetic factors 
found in eastern countries may influence the frequency 
of the disease. For example, HLA‑B51, a kind of human 
leucocyte antigen, has a higher prevalence among the 
inhabitants of the “silk route”.[4] However, BD appears to 
be less frequent among Japanese immigrants in the US 
and Turkish immigrants in Germany, suggesting the role of 
environmental factors in the development of the disease.[4]
Pathophysiology
In spite of the several immunological components 
demonstrated, the exact mechanism which leads to 
the inflammatory changes remains obscure. A plausible 
hypothesis is that an infectious agent or an autoantigen, 
such as heat shock proteins (HSP), triggers an 
inflammatory reaction that leads to the disease, in 
genetically predisposed individuals.[23] Oral microbial flora 
also has been implicated in the pathophysiology, as BD 
starts mostly with symptoms of the oral mucosa.[27]
Genetic factors play an important role in the development 
of BD. Ohno et al. has first described the association 
between the disease and HLA‑B5(51) in 1973.[28] A 
meta‑analysis showed that carriers of HLA‑B51/B5 have 
an increased risk of developing the disease when 
compared with non‑carriers (OR: 5.78).[26]
It has been proposed that the genetic susceptibility 
induces the overexpression of pro‑inflammatory cytokines, 
such as Th1 and Th17, thus enhancing the inflammatory 
reaction in BD.[12] The organs affected by the disease show 
significant infiltration by lymphocytes and neutrophils.[10]
Clinical features
The typical features of BD include mucocutaneous 
lesions. Oral and genital ulcers, together with cutaneous, 
Figure 1: Lesion with hypersignal on T2 in the regions of midbrain 
and right parahippocampus
Figure 2: Hyperintense lesion on T2 at the midbrain peduncle, 
mimicking a mesencephalic tumor
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ocular, and articular lesions are the most frequent features 
of the disease in all countries.[4] Oral ulcers consist of 
recurrent and painful ulcerations of the oral mucosa. 
The most common sites include lips, buccal mucosa, 
tongue, and soft palate. It starts as a slightly raised and 
erythematous area with vesicle‑pustules, evolving into an 
ulcer within 2–3 days, with rolled borders and a grayish 
yellow necrotic base.[5] These lesions can be debilitating, 
affecting eating, drinking, and swallowing. Healing is 
typically spontaneous within one to three weeks.
The genital ulcers are similar in appearance and course 
to the oral ones. They are most commonly found on 
the scrotum in men and the vulva in women. They are 
usually deeper and have a tendency to scar and are also 
debilitating.[5] Other important cutaneous lesions are 
erythema nodosum‑like lesions, papulopustular lesions, 
and superficial thrombophlebitis.[5]
Other symptoms of BD include ocular, vascular, 
gastrointestinal, and neurological involvement. Recent 
studies demonstrated that these other lesions can 
have their onsets later in the course of the disease (5–
10 years).[6] Usually, BD starts with relatively milder 
manifestations.
Diagnosis
The diagnosis of BD is primarily based on clinical 
criteria following the exclusion of other conditions. The 
International Study Group for Behçet’s Disease Criteria 
consists of presence of recurrent oral ulcers, plus any two 
of recurrent genital ulcers, typical ocular lesions, typical 
cutaneous lesions, or a positive skin pathergy test (SPT).
An international team developed new criteria under 
the name International Criteria for Behçet’s Disease, 
briefly “ICBD” criteria, which were published in 2006. 
These new criteria were revised in 2013, becoming the 
17th set of classification/diagnosis criteria for BD. In this 
criteria, oral ulcers ( OU), genital ulcers (GU) and ocular 
manifestations get each 2 points, and others (skin lesions, 
neurological manifestations, vascular manifestations, and 
positive SPT) get 1 point. If a patient gets 4 points or 
more, the patient is diagnosed as having BD.[18]
Neurological features
Neurological involvement is one of the most serious 
causes of morbidity and mortality in BD.[21] The 
frequency of neurological involvement varies, based on 
the sample studied and the definition of neurological 
involvement. It seems that neuro‑Behçet’s disease (NBD) 
is more frequent in men than in women.[2,19] The age of 
onset is usually 20–40 years. Neurological manifestations 
commonly develop a few years after the onset of BD. 
Few patients with BD starts systemic manifestations with 
neurological symptoms.[1,19]
There are two categories of CNS involvement in BD: 
parenchymal or non‑parenchymal. In the first, the 
principal finding is meningoencephalitis. Lesions can 
occur in brainstem, spinal cord, in the brain, or be 
diffuse.[2] At the end, vascular complications involving 
thrombosis of large vessels (typically veins) occur.[2] 
Every time that an initial diagnosis of NBD is predicted, 
infectious and neoplastic disorders must be ruled out.
It is important to note that NBD is an inflammatory 
perivasculitis.[14] So, the blood vessel walls are not 
infiltrated and there is no evidence for endothelial cell 
necrosis. The structures affected can be confirmed by 
MRI, where striking atrophy can be seen.[20,22]
Making a NBD diagnosis is easier when the patient has 
systemic findings of the disease. Also, it is uncommon 
for BD to arise in the absence of systemic features. No 
validated criteria exist.[2]
The characteristic MRI lesion in parenchymal 
involvement is an upper brainstem lesion that extends 
into the thalamus and basal ganglia on one side. Bilateral 
lesions are less common.[20,22] Hyperintense T2 gives 
a better visualization and are often associated with 
edema.[20,22] Comparing the findings of MRI studies, these 
lesions were hyper intense on both gadolinium enhanced 
T1‑weighted images (WI) and T2WI.[16]
In the acute phase, most patients have single lesions, but 
in the chronic phase, more diffuse involvement is noted, 
making it difficult to differentiate between NBD and 
multiple sclerosis.[9] The most common neuropathological 
findings in patients with BD are focal necrotic lesions in 
the brain.[17] Severe and acute inflammation consisting 
mainly of lymphocytic and neutrophilic infiltrations 
of the perivascular spaces and parenchyma can lead to 
necrotizing and disseminated encephalitis.[11,15]
CSF constituent are altered in around 70–80% of patients 
with parenchymal complications.[2] CSF protein is 
modestly raised in most cases.[6] Cell count is often raised 
and CSF, and neutrophilia is found in the early stages, 
being replaced later by lymphocytosis.[2]
Subacute meningoencephalitis accounts for 75% of cases 
in parenchymal NBD.[2] Usually, this feature accompanies 
the exacerbation of systemic features of BD.[3] Headache 
is common before and during the attack. Many syndromes 
might be encountered during the course of parenchymal 
NBD. Signs of brainstem involvement include 
ophthalmoparesis, cranial neuropathy, and cerebellar or 
pyramidal dysfunction.[2] Symptoms suggestive of cerebral 
hemispheric involvement include encephalopathy, 
hemiparesis, hemisensory loss, seizures and dysphagia, 
depending of the location of the lesion. Ischemic stroke 
and epilepsy are uncommon in BD.[2]
Brain tumor‑like NBD
Few cases of NBD mimicking a brain tumor have been 
reported. The earliest case was reported in 1987.[24] 
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Matsuo et al. have reported a case and reviewed previous 
reports.[25] These were predominantly large lesions, 
involving the commonly affected areas in NBD (braistem, 
diencephalon, basal ganglia, and internal capsule).[2,24,30] 
Most cases have been diagnosed after lesion biopsy, and 
respond to treatment with corticosteroids.
Differential diagnosis is extensive. It includes infectious 
causes (viral, bacterial, fungal), uveomeningitic 
syndromes (sarcoid, SLE, Sjögren), Neoplastic causes, 
complications of other systemic diseases or complications 
of treatment for BD (drug induced‑meningitis, infections 
with immunosuppression).
Patients who have an acute parenchymal inflammatory 
episode usually recover well with corticosteroid 
treatment.[2] Around 20–30% of them stands with residual 
neurological impairment.[1,32] The chief pathological 
changes of vascular BD is aneurysm formation of 
the peripheral arteries.[13,16] CNS involvement occurs 
mostly late in the course of the disease.[17,31] The 
mortality reported by Wolf et al. in patients with NBD 
was 41%.[33] Our case report shows the importance 
of differential diagnosis in lesions with tumoral 
characteristics in mesencephalon and thalamus. History 
of recurrent oral ulcers should suggest Neuro‑Behçet, 
avoiding biopsy in this cases and being initiated empiric 
treatment with corticosteroids.
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